WednesdayDec 28, 2022 9:00 am

M&A Activity Keeps Flora Growth Corp. (NASDAQ: FLGC) Revenues Strong Amid Expected Rebound in Cannabis Industry

Cannabis cultivator and international brand developer Flora Growth has continued to build its revenues through accretive acquisitions during the past year and expects to see revenues continue to rise amid further M&A activityFlora expects to lock in its latest acquisition by the end of the month after shareholders meet to discuss the proposed deal with multi-national operator Franchise Global Health (“FGH”), which would grant Flora immediate access to Germany’s cannabis market and FGH the ability to overcome supply chain difficultiesFlora has previously reported cooperative agreements that increase its product distribution pipeline in Europe through Switzerland and the Czech Republic In…

Continue Reading

TuesdayDec 27, 2022 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals

Studies have indicated that around 40% of the available drugs on the market offer poor bioavailabilityLexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral deliveryThe global pharmaceutical drug delivery market was valued at $1.66 billion in 2021 and is expected to grow at a CAGR of 5.9%, resulting in a value of $2.21 billion by 2026 One of the main concerns associated with marketed drugs is low bioavailability. Bioavailability is the amount of a drug or substance that becomes completely available to the intended biological destination and is…

Continue Reading

ThursdayDec 22, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations

CNS Pharmaceuticals is a biopharmaceutical company that focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous systemThe company is currently evaluating the efficacy of Berubicin, a novel anthracycline that appears to cross the blood-brain barrier, in a potentially pivotal Phase 2 trial involving patients with recurrent glioblastoma multiforme (“GBM”)CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event in which he provided an update on recent key events and plans for the future in addition to allaying the investors’ concerns regarding the recent reverse stock splitCNS Pharmaceuticals also announced the…

Continue Reading

ThursdayDec 22, 2022 9:00 am

Luis Merchan, Helping Flora Growth Corp. (NASDAQ: FLGC) Become Global Leader in the CBD Space

Luis Merchan was appointed President of Consumer Goods at Flora in July 2020 before being appointed as the company’s CEO five months later, and chairman of its Board of Directors in May 2022Merchan would lend his years of experience at Macy’s, where he led various sales and marketing initiatives, including the B2B corporate team responsible for bringing in $160 million in annual revenue Under his leadership, Flora has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide. Mr. Merchan has also spearheaded several M&As, all of which have since set the company up…

Continue Reading

ThursdayDec 15, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

Lexaria has multiple studies planned that will commence early in 2022DehydraTECH increases Lexaria’s ability to leverage multiple markets, including the growing CBD sector, which is expected to meet and exceed $108 billion in revenue by 2027DehydraTECH can increase the efficacy of the drugs being administered, offering faster absorption and lowering the delivery time According to the Epilepsy Foundation, epilepsy is the fourth most common neurological condition globally, affecting one in every 26 people. About 48 out of every 100,000 people are diagnosed with the condition every year, and as of 2019, it affected approximately 50 million people ( With the…

Continue Reading

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarterThe company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials in mid-2023Through…

Continue Reading

WednesdayDec 14, 2022 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Remains Committed to Improving Road Safety Through Development of Lidar Solutions for Assisted and Autonomous Driving

Nearly all automotive OEMs have plans to include lidar sensors within their assisted and automated driving platformsGaining public trust in the ability of vehicles to operate safely while providing automated driving features will be a key milestone for widespread adoptionL2+/L3 ADAS is likely to be an enabler as it helps ease the public with broader hands-free functions while maintaining the ability to take over as neededCepton’s lidar sensors are uniquely positioned to benefit from these core industry growth trends and the Company remains committed to delivering superior driving experiences with added safety and convenience Automotive OEMs have made headlines recently…

Continue Reading

TuesdayDec 13, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugsIn calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreementsLexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks)The company has also started investigating DehydraTECH-CBD as a potential therapeutic for…

Continue Reading

MondayDec 12, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatmentCNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levelsCNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and EuropeBerubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan Drug status The…

Continue Reading

MondayDec 12, 2022 9:45 am

Vision Energy Corp. (VENG) Announces Ticker Change and Engages Rho Adviseurs for Planning Services in the Development of Europe’s First Green and Low-Carbon Energy Terminal

Rho Adviseurs has been engaged by Vision Energy, a growing renewable energy facilities developer, to provide specialist studies for environmental impact assessment and policy, process guidance, and spatial planning, all required for the permit applications for Vision’s Green Energy HubVision Energy’s Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products, and located in the North Sea Port of Vlissingen at the mouth of the Westerschelde estuaryVision Energy is focused on governments that support regulatory standards promoting hydrogen production and alternatives to traditional fossil fuels in support of green energy solutions…

Continue Reading

Contact us: (310) 299-1717